Supplier Review
Reviewed March 17, 2026
Is AmbioPharm legit?
The buyer-side answer is to separate a substantial public profile from the specific procurement file.
As of March 17, 2026, AmbioPharm publicly describes itself as a large peptide API manufacturer
with a U.S. headquarters in North Augusta, South Carolina and facilities in Shanghai, China, producing
new chemical entities and generic peptides under GMP for global clients. Those are meaningful public
claims, but they still need to be reconciled against the exact legal entity, site, and material relevant
to your order.
Public claims reviewed
- AmbioPharm says it has U.S. headquarters in North Augusta, South Carolina.
- AmbioPharm says it operates facilities in Shanghai, China.
- AmbioPharm says it manufactures new chemical entities and generic peptides under GMP.
- AmbioPharm presents itself as a large-capacity peptide API manufacturer serving clients worldwide.
Source reviewed March 17, 2026:
AmbioPharm 2024 brochure.
What a buyer should verify next
- Which AmbioPharm legal entity is quoting, contracting, and responsible for release.
- Which facility would actually handle the material being sourced.
- Whether the GMP and capacity claims apply directly to the product class and scope you need.
- Whether the COA, batch records, and commercial paperwork reconcile cleanly with that entity and site.
When a paid screen is justified
- The order or program value is meaningful enough that entity/site confusion creates real risk.
- The public footprint looks strong but the commercial file is narrower or less specific.
- Your buying decision depends on whether the quoted material truly sits inside the represented GMP scope.
APV view
AmbioPharm appears to be a substantial operating company, but buyers should still verify the exact
entity, manufacturing path, GMP relevance, and document coherence before treating the public profile
as enough qualification evidence.